Skip to main content

Table 2 Methods to enhance the anti-fibrosis effect of MSC-EVs in different organs

From: Mesenchymal stem cell-derived extracellular vesicles in therapy against fibrotic diseases

  Exogenous modification Bio-gel Preconditioning
Liver miR-122 [55] PEG hydrogels [58] IFN-γ [59]
  miR-181-5p [56]   
  mmu_circ_0000623 [57]   
  miR-145-5p [7]   
Kidney KMP2 [61] RGD hydrogels [63] Oct-4 overexpression [65]
  GDNF [62] Collagen matrix [64]
Heart miR-146a [71] PGN hydrogels [68] FNDC5 or irisin [73]
  IMTP [72] Alginate hydrogels [69] HIF-1α [74]
   (RADA)4-SDKP hydrogels [70] B2M-deficient [75]
    Ischemia [76]
    Hypoxia [77]
Skin TSG-6 [78] BSSPD hydrogels [79]  
Tendon adhesion    Hydroxycamptothecin [80]
Urethra    TNFα [81]
  1. MSCs, mesenchymal stem cells; MSC-EVs, mesenchymal stem cell-derived extracellular vesicles